Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11936MR)

This product GTTS-WQ11936MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11936MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9054MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ13046MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ5715MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ13731MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ11069MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ2368MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ9071MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ5636MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP870
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW